Abstract:Objective To map the diverse health outcomes associated with serum uric acid (SUA) levels.Design Umbrella review.Data sources Medline, Embase, Cochrane Database of Systematic Reviews, and screening of citations and references.Eligibility criteria Systematic reviews and meta-analyses of observational studies that examined associations between SUA level and health outcomes, meta-analyses of randomised controlled trials that investigated health outcomes related to SUA lowering treatment, and Mendelian randomisation studies that explored the causal associations of SUA level with health outcomes.Results 57 articles reporting 15 systematic reviews and144 meta-analyses of observational studies (76 unique outcomes), 8 articles reporting 31 meta-analyses of randomised controlled trials (20 unique outcomes), and 36 articles reporting 107 Mendelian randomisation studies (56 unique outcomes) met the eligibility criteria. Across all three study types, 136 unique health outcomes were reported. 16 unique outcomes in meta-analyses of observational studies had P<10-6, 8 unique outcomes in meta-analyses of randomised controlled trials had P<0.001, and 4 unique outcomes in Mendelian randomisation studies had P<0.01. Large between study heterogeneity was common (80% and 45% in meta-analyses of observational studies and of randomised controlled trials, respectively). 42 (55%) meta-analyses of observational studies and 7 (35%) meta-analyses of randomised controlled trials showed evidence of small study effects or excess significance bias. No associations from meta-analyses of observational studies were classified as convincing; five associations were classified as highly suggestive (increased risk of heart failure, hypertension, impaired fasting glucose or diabetes, chronic kidney disease, coronary heart disease mortality with high SUA levels). Only one outcome from randomised controlled trials (decreased risk of nephrolithiasis recurrence with SUA lowering treatment) had P<0.001, a 95% prediction interval excluding the null, and no large heterogeneity or bias. Only one outcome from Mendelian randomisation studies (increased risk of gout with high SUA levels) presented convincing evidence. Hypertension and chronic kidney disease showed concordant evidence in meta-analyses of observational studies, and in some (but not all) meta-analyses of randomised controlled trials with respective intermediate or surrogate outcomes, but they were not statistically significant in Mendelian randomisation studies.Conclusion Despite a few hundred systematic reviews, meta-analyses, and Mendelian randomisation studies exploring 136 unique health outcomes, convincing evidence of a clear role of SUA level only exists for gout and nephrolithiasis.

Serum Uric Acid Levels of Patients with Multiple Sclerosis and Other Neurological Diseases

Serum Uric Acid Levels and Neuromyelitis Optica.

Association of Serum Uric Acid Levels in Meige's Syndrome.

Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies

[Serum Uric Acid Level and Related Clinical Features in Neuromyelitis Optica].

Serum Uric Acid and Risk of Incident Chronic Kidney Disease: a National Cohort Study and Updated Meta-Analysis.

Serum Uric Acid Levels in Neurodegenerative Disorders: A Cross-Sectional Study.

Serum uric acid level and related clinical features in high risk syndrome of neuromyelitis optica

[Association of Serum Uric Acid Level with Amyotrophic Lateral Sclerosis].

Cerebrospinal fluid uric acid levels associated with disease severity in patients with anti- N -methyl-d-aspartate receptor encephalitis

The Correlation Between Serum Uric Acid Level and Abdominal Obesity or Metabolic Syndrome

Correlation Between Serum Uric Acid Levels and Clinical Characteristics in Patients with Longitudinally Extensive Transverse Myelitis A Case-Control Study

Relation of Uric Acid Levels to Aortic Root Dilatation in Hypertensive Patients with and Without Metabolic Syndrome

Serum Bilirubin Concentrations and Multiple Sclerosis

Association Between Serum Uric Acid Levels and Cerebral White Matter Lesions in Chinese Individuals

Serum Uric Acid Levels Predict Mortality Risk in Male Amyotrophic Lateral Sclerosis Patients

Serum Uric Acid Levels and the Clinical Characteristics of Depression.

Lower serum uric acid levels in cerebral amyloid angiopathy: a pilot study

Serum uric acid a depression biomarker.

Serum Levels of Homocysteine, Vitamin B12 and Folate in Patients with Multiple Sclerosis: an Updated Meta-Analysis.

Associations of serum uric acid variability with neuroimaging metrics and cognitive decline: a population-based cohort study